Raquel Castellanos, Deputy Director of Scientific Programs and Strategic Initiatives at AACR, shared a post on LinkedIn:
“The 12 New Drugs on the Horizon presentation titles for the AACR Annual Meeting 2026 are now public, spanning three sessions that will showcase some of the most cutting-edge advances in cancer therapeutics.
These sessions have become a cornerstone of the Annual Meeting, offering an exclusive first look at cutting-edge therapeutic advances poised to shape the future of cancer research and treatment. From molecular glue degraders and bispecific antibodies to next-generation ADCs and T cell engagers, these first-time disclosures offer an early glimpse into therapies that are poised to shape the treatment landscape.
A special thank you to the AACR Chemistry in Cancer Research (CICR) Working Group for their continued leadership in driving this signature initiative. Year after year, their vision ensures that New Drugs on the Horizon remains a premier stage for breakthrough science.
Join us in San Diego to experience these discoveries as they are unveiled. Abstracts will be revealed on the day of the presentations.”
Other articles featuring AACR on OncoDaily.
